Amorphous Benzimidazole Stabilization via Basic Inorganic Salts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amorphous benzimidazole compounds with proton pump inhibitor activity are unstable, particularly in acidic environments and when exposed to water, leading to degradation and color changes, which complicates their use in solid dosage forms like tablets and capsules, and existing stabilization methods, such as enteric coating, can cause adverse reactions like burping.
Innovation Solution
A stable solid dosage form is created by blending amorphous benzimidazole compounds with non-toxic bases like basic inorganic salts and forming enteric or controlled release coating layers to stabilize the compounds, preventing direct contact with acidic substances and enhancing stability during manufacturing and storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amorphous benzimidazole compounds are used as proton pump inhibitors, then proton pump inhibitor activity is achieved, but stability deteriorates due to instability toward water and acids
Solution Approach 1:
The patent introduces a basic inorganic salt (magnesium carbonate, calcium carbonate, magnesium hydroxide, or magnesium oxide) as an intermediary substance that mediates between the amorphous benzimidazole compound and the acidic environment. This base stabilizer neutralizes acid and prevents direct degradation of the unstable compound, enabling the compound to maintain stability while retaining proton pump inhibitor activity
Solution Approach 2:
The patent changes the chemical environment parameters by introducing a basic substance that alters the local pH around the amorphous benzimidazole compound. This parameter change (increasing pH) transforms the unstable acidic environment into a more stable basic environment, preventing degradation while maintaining the compound's pharmacological activity
2Stability of the object's composition
If enteric coating is applied to protect from acid, then stability improves, but harmful effects increase due to burping and adverse reactions
Solution Approach 1:
The basic inorganic salt acts as an intermediary that provides acid neutralization without requiring enteric coating. This alternative mechanism protects the compound from acid degradation while avoiding the gastrointestinal side effects associated with enteric coating, such as burping and adverse reactions
Solution Approach 2:
The patent converts the harmful effect of acid exposure into a beneficial process by using the basic inorganic salt to neutralize the acid. Instead of preventing acid contact through coating (which causes burping), the base stabilizer transforms the acidic environment into a neutral/basic one, eliminating the harmful effect while maintaining stability
3Ease of operation
If amorphous benzimidazole compounds are formulated in solid dosage forms, then medicinal use is enabled, but stability deteriorates due to interactions with other ingredients
Solution Approach 1:
The basic inorganic salt serves as a stabilizing intermediary that protects the amorphous benzimidazole compound from degradation by other ingredients in the dosage form. This base stabilizer creates a protective chemical environment that maintains compound stability throughout the formulation and storage process
Solution Approach 2:
The introduction of the basic inorganic salt changes the chemical parameters of the dosage form by establishing a basic pH environment. This parameter change prevents acid-catalyzed degradation and maintains the stability of the amorphous compound throughout the formulation, enabling successful medicinal use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution significantly stabilizes amorphous benzimidazole compounds, preventing degradation and color changes, and reduces adverse reactions, allowing for effective use in medicinal formulations with improved stability and patient compliance.
Implementation Method 1
they are very unstable to acids and become extremely unstable in aqueous solution or suspension as the pH of the solution or suspension decreases
Implementation Method 2
an enteric coating layer is applied expecting that a benzimidazole compounds are not dissolved in the stomach having a low pH value
Data Source
AI summary
It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.